Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of chronic myelomonocytic leukemia

Treatment of chronic myelomonocytic leukemia Since chronic myelomonocytic leukemia (CMML) has been classified within myelodysplastic syndromes (MDS) for a long time, most treatment data are derived from MDS trials. Owing to the limited number of CMML patients included in these trials, results are analyzed for the whole study population rather than for CMML patients as a distinct group. CMML patients with a myeloproliferative type of disease were often excluded. Therefore, generalization of data gained from MDS trials is very problematic. This review provides a brief overview of the treatment possibilities for patients with CMML. The paucity of existing clinical trials underlines the importance of including CMML patients into clinical studies whenever possible. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Treatment of chronic myelomonocytic leukemia

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/treatment-of-chronic-myelomonocytic-leukemia-1dXpN6vLfH
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0291-3
Publisher site
See Article on Publisher Site

Abstract

Since chronic myelomonocytic leukemia (CMML) has been classified within myelodysplastic syndromes (MDS) for a long time, most treatment data are derived from MDS trials. Owing to the limited number of CMML patients included in these trials, results are analyzed for the whole study population rather than for CMML patients as a distinct group. CMML patients with a myeloproliferative type of disease were often excluded. Therefore, generalization of data gained from MDS trials is very problematic. This review provides a brief overview of the treatment possibilities for patients with CMML. The paucity of existing clinical trials underlines the importance of including CMML patients into clinical studies whenever possible.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Oct 25, 2016

References

  • World Health Organization Classification of Tumours: Tomours of the Haematopoietic and Lympoid Tissues
    Vardiman, JW; Pierre, R; Bain, B; Bennett, JM; Imbert, M; Brunning, RD
  • The 2016 revision to the World Health Organization classfication fo myeloid neoplasms an acute leukemia
    Arber, DA; Orazi, A; Hasserjian, R; Thiele, J; Borowitz, MJ; Beau, MM
  • Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistolog
    Orazi, A; Chiu, R; O’Malley, DP; Czader, M; Allen, SL; An, C
  • Problems in the classification of CMML-dysplastic versus proliferative type
    Germing, U; Gattermann, N; Minning, H; Heyll, A; Aul, C
  • Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases
    Fenaux, P; Beuscart, R; Lai, JL; Jouet, JP; Bauters, F
  • Chronic myelomonocytic leukemia
    Storniolo, AM; Moloney, WC; Rosenthal, DS; Cox, C; Bennett, JM
  • Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
    Schuler, E; Schroeder, M; Neukirchen, J; Strupp, C; Xicoy, A; Kündgen, A; Hildebrandt, B; Haas, R; Gattermann, N; Germing, U
  • The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposal by the French-American-British Cooperative Leukaemia Group
    Bennett, JM; Catovsky, D; Daniel, MT; Flanskin, G; Galton, DA; Gralnick, H
  • Prognostic score including gene mutations in chronic myelomonocytic leukemia
    Itzykson, R; Kosmider, O; Renneville, A; Gelsi-Boyer, V; Meggendorfer, M; Morabito, M
  • An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
    Padron, E; Garcia-Manero, G; Patnaik, MM; Itzykson, R; Lasho, T; Nazha, A
  • Clinical and biological implications of driver mutations in myelodysplastic syndromes
    Papemmanuil, E; Gerstung, M; Malcovati, L; Tauro, S; GunemG; Loo, P
  • Clonal architecture of chronic myelomonocytic leukemia
    Itzykson, R; Kosmider, O; Renneville, A; Morabito, M; Preudhomme, C; Berthon, C
  • A Randomized Trial of Hydroxyurea Versus VP16 in Adult Chronic Myelomonocytic Leukemia
    Wattel, E; Guerci, A; Hecquet, B; Economopoulos, T; Copplestone, A; Mahe, B; Couteaux, ME; Resegotti, L; Voglova, V; Foussard, C; Pegourie, B; Michaux, JL; Doconinck, E; Stoppa, AM; Mufti, G; Oscier, D; Fenaux, P
  • Results of topotecan single-agent theray in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Beran, M; Estey, E; O’Brien, S
  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, P; Mufti, GJ; Hellstrom-Lindberg, E; Santini, V; Finelli, C; Giagounidis, A
  • Activity of Azacitidine in Chronic Myelomonocytic Leukemia
    Costa, R; Abdulhaq, H; Haq, B; Shadduck, RK; Latsko, J; Zenati, M
  • High rate of remissions in chronic myelomonoctic leukemia treated with 5‑azacytidine: results of an Italian retrospective study
    Fianchi, L; Criscuolo, M; Breccia, M; Maurillo, L; Salvi, F; Mansueto, G
  • Treatment of chronic myelomonocytic leukemia with 5‑Azacytidine; a case series and literature review
    Thorpe, M; Montalvao, A; Pierdomenico, F; Moita, F; Almeida, A
  • Treatment of chronic myelomonocytic leukemia with azacitidine
    Wong, E; Seymour, JF; Kenealy, M; Westerman, D; Herbert, K; Dickinson, M
  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
    Adès, L; Sekeres, MA; Wolfromm, A; Teichman, ML; Tiu, RV; Itzykson, R
  • Azacitidine in CMML: matched-pair analysis of daily-life patients reveal modest effects on clinical course and survival
    Pleyer, L; Germing, U; Sperr, WR; Linkesch, W; Burgstaller, S; Stauder, R
  • On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
    Feldman, E; Cortes, J; DeAngelo, DJ
  • Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
    Sliitonen, T; Timonen, T; Juvonen, E
  • Multi-Institutional Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
    Padron, E; Dezern, A; Andrade-Campos, M; Vaddi, K; Scherle, P; Zhang, Q
  • Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    Kröger, N; Zabelina, T; Guardiola, P; Runde, V; Sierra, J; Biezen, A; Niederwieser, D; Zander, AR; Witte, T
  • Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia
    Mittal, P; Saliba, RM; Giralt, SA; Shahjahan, M; Cohen, AI; Karandish, S; Onida, F; Beran, M; Champlin, RE; Lima, M
  • Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
    Krishnamurthy, P; Lim, ZY; Nagi, W; Kenyon, M; Mijovic, A; Ireland, R; Marsh, J; Ho, AYL; Mufti, GJ; Pagliuca, A
  • Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival is Determined by Karyotype and Comorbidities
    Eissa, H; Gooley, TA; Sorror, ML; Nguyen, F; Scott, BL; Doney, K; Loeb, KR; Martin, PJ; Pagel, JM; Radich, JP; Sandmaier, VM; Warren, EH; Storb, R; Appelbaum, FR; Deeg, J
  • Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patietns with chronic myelomonocytic leukemia
    Kongtim, P; Popat, U; Jimenez, A